Literature DB >> 3179150

A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery.

H M Mathews1, I W Carson, S M Lyons, I A Orr, P S Collier, P J Howard, J W Dundee.   

Abstract

Midazolam 0.3 mg kg-1 was given as a single dose to three groups of children undergoing cardiac surgery to determine its pharmacokinetic profile in this situation. The first group, undergoing closed heart surgery, received the midazolam during the operation. The other groups underwent cardiopulmonary bypass (CPB) with and without complete circulatory arrest. Mean clearance was 512 ml kg-1 h-1 and mean elimination half-lives were 3.3 h following CPB, with a tendency to a higher clearance in those children who had not undergone bypass. In a subsequent part of the study, 10 children received an infusion of midazolam 0.05 mg kg-1 h-1, in combination with intermittent doses of morphine, in the postoperative period. Mean plasma midazolam concentrations consistent with adequate sedation were 80-100 ng ml-1 during the infusion. One child who had not undergone CPB had very low plasma concentrations of midazolam with the same rate of infusion, consistent with the tendency for higher clearance in this group in the bolus pharmacokinetic study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179150     DOI: 10.1093/bja/61.3.302

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

1.  Pharmacokinetics of midazolam in critically ill pediatric patients.

Authors:  M C Nahara; J McMorrow; P R Jones; D Anglin; R Rosenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Sedation in pediatric patients.

Authors:  S Suresh; S C Hall
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

4.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

Authors:  Sven Björkman
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

Review 7.  Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.

Authors:  Ibrahim Ince; Catherijne A J Knibbe; Meindert Danhof; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

8.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

Review 9.  Clinical pharmacology of midazolam in neonates and children: effect of disease-a review.

Authors:  Gian Maria Pacifici
Journal:  Int J Pediatr       Date:  2014-02-18

Review 10.  Inter-individual variation in midazolam clearance in children.

Authors:  Mohammed I Altamimi; Helen Sammons; Imti Choonara
Journal:  Arch Dis Child       Date:  2014-10-03       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.